SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

• Sponsor: Ruijin Hospital (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05185869
• Collaborator: (none)
• Enrollment: 58
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 45
• Patients Per Site Per Month: 1.3

Study Details

Study Description

Brief Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of SHR6390 in combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with advanced/metastatic pancreatic cancer.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer	Drug: SHR6390; Drug: Nab-paclitaxel; Drug: Gemcitabine	Phase 2

Detailed Description

This is an open-label, prospective, single-center, single-arm, Simon's two-stage design phase II study for unresectable advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) subjects treated with SHR6390 plus nab-paclitaxel and gemcitabine.

In this research study, the main objectives include:

1. Evaluate objective response rate in patients with pancreatic cancer receiving SHR6390 plus nab-paclitaxel and gemcitabine.

2. Assess adverse side effects associated with the combination of SHR6390 with nab-paclitaxel and gemcitabine.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 58 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of SHR6390 Plus Nab-paclitaxel and Gemcitabine in Unresectable Advanced/Metastatic Pancreatic Ductal Adenocarcinoma
• Anticipated Study Start Date: Jan 1, 2022
• Anticipated Primary Completion Date: Jul 1, 2025
• Anticipated Study Completion Date: Oct 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: AG+SHR6390 Subjects will receive SHR6390 plus nab-paclitaxel and gemcitabine	Drug: SHR6390; SHR6390, Oral Administration; Drug: Nab-paclitaxel; Paclitaxel-albumin, Intravenous Injection; Drug: Gemcitabine; Gemcitabine, Intravenous Injection

Outcome Measures

Primary Outcome Measures

1. Objective Response Rate (ORR) [Up to 2 years.]

   ORR is defined as the proportion of patients with best objective response of confirmed complete response (CR) or partial response (PR) according to RECIST1.1.

2. Adverse Events (AEs) [From the first drugs administration to within 30 days for the last treatment.]

   AEs were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.

Secondary Outcome Measures

1. Overall Survival (OS) [Up to 2 years.]

   OS is defined as the time from the first drugs administration to the date of death due to any cause or the last follow ship.

2. Progression Free Survival (PFS) [Up to 2 years.]

   PFS is defined as the time from the first drugs administration to the date of disease progression or the last follow ship.

3. Disease Control Rate (DCR) [Up to 2 years.]

   DCR is defined as the rate of participants who have achieved complete response, partial response and stable disease.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Male or female of 18 to 75 years old;

2. Subjects are diagnosed with histologically confirmed unresectable advanced or metastatic pancreatic ductal adenocarcinoma with at least one measurable lesion according to the RECIST 1.1 standard (the CT scan length of the tumor lesion > 10 mm);

3. Subjects are naïve to systemic treatment;

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;

5. Life expectancy ≥12 weeks;

6. Adequate organ performance based on laboratory blood tests;

7. The toxicity of the previous treatment has been restored to ≤1 level (if there is surgery, the wound has completely healed);

8. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation;

9. Normal swallowing function;

10. Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures.

Exclusion Criteria:

1. Had other active malignant tumors within 5 years before entering the study;

2. Confirmed or suspicious new metastatic lesion in brain;

3. Subjects are allergy to experimental drugs or any excipients;

4. Coagulation disorders (INR>1.5, APTT>ULN);

5. Severe pleural effusion or ascites;

6. Severe and uncontrolled medical diseases, acute infections; recent history of major surgery for myocardial infarction (within 3 months);

7. Subjects combined with other anti-tumor drugs;

8. Chronic diarrhea or intestinal obstruction;

9. Pregnant or lactating women; Fertile subjects who are unwilling or unable to take effective contraceptive measures;

10. Subjects in any trial drug treatment;

11. Severe mental disorder;

12. Other situations that investigators considered should be excluded.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ruijin Hospital Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai	China	200025

Sponsors and Collaborators

• Ruijin Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ruijin Hospital
• ClinicalTrials.gov Identifier: NCT05185869
• Other Study ID Numbers: PANC-1st-IIT-SHR6390-AG
• First Posted: Jan 11, 2022
• Last Update Posted: Jan 11, 2022
• Last Verified: Oct 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Pancreatic Neoplasms; Gemcitabine; Paclitaxel

Study Results

No Results Posted as of Jan 11, 2022